Cannabics Pharmaceuticals study shows CBC, CBG exhibit anti-tumor properties on cancer cells

Bethesda-based Cannabics Pharmaceuticals Inc., which works with personalized cannabinoid medicine focused on cancer and its side effects, announced Monday that in a series of tests conducted at the company's High Through-put Screening facility in Israel, cannabinoids CBC (Cannabichromene) and CBG (Cannabigerol) both exhibit anti-tumor properties, tested on human gastrointestinal cancer cells. CBC is an additional non-psychoactive cannabinoid and is ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *